|
Patent landscape, scope, and claims: |
Scope and claims analysis for US Patent 6,251,895 (olanzapine dihydrate D): The patent estate is anchored on a single crystalline form, “olanzapine dihydrate D,” defined by specific X-ray powder diffraction (XRPD) peak positions and relative intensities. Claim scope expands from the crystalline form itself into “substantially pure” material, limits on residual conversion to “dihydrate B,” downstream pharmaceutical formulations (including aqueous suspensions and tablets), and medical use claims for treating psychotic and selected anxiety/psychosis conditions. A separate process claim covers crystallization of dihydrate D from technical-grade olanzapine in aqueous solvent under defined time windows, with optional wetting agent and mild drying to avoid desolvation. In litigation or generic development contexts, the XRPD-defined form and the B impurity cap drive the most actionable infringement and design-around risk.
US Patent 6,251,895 scope: what patents protect olanzapine dihydrate D defined by XRPD peaks?
What is the core claim subject matter?
Independent claim theme: olanzapine dihydrate D as a defined crystalline solid.
Claim 1 defines “olanzapine dihydrate D” by an XRPD pattern comprising the following interplanar spacings (d, Å):
- 9.4511, 7.7098, 7.4482, 6.9807, 6.5252, 5.7076, 5.5539, 5.223, 4.9803, 4.8908, 4.784, 4.6947, 4.4271, 4.3956, 4.3492, 4.2834, 4.1156, 3.7837, 3.7118, 3.5757, 3.482, 3.3758, 3.3274, 3.2413, 3.1879, 3.135, 3.0979, 3.016, 2.9637, 2.907, 2.8256, 2.7914, 2.7317, 2.6732, 2.5863
Claim 2 further limits Claim 1 by adding the relative intensities (I/I1) for the listed d-spacings:
- d 9.4511 has 100.00
- d 7.7098 has 14.23
- d 7.4482 has 22.43
- d 6.9807 has 5.73
- d 6.5252 has 5.45
- d 5.7076 has 4.24
- d 5.5539 has 1.60
- d 5.223 has 62.98
- d 4.9803 has 22.21
- d 4.8908 has 15.03
- d 4.784 has 27.81
- d 4.6947 has 5.15
- d 4.4271 has 13.00
- d 4.3956 has 16.63
- d 4.3492 has 34.43
- d 4.2834 has 51.38
- d 4.1156 has 18.32
- d 3.7837 has 5.30
- d 3.7118 has 1.56
- d 3.5757 has 0.71
- d 3.482 has 9.39
- d 3.3758 has 24.87
- d 3.3274 has 13.49
- d 3.2413 has 5.97
- d 3.1879 has 1.04
- d 3.135 has 3.18
- d 3.0979 has 1.43
- d 3.016 has 1.95
- d 2.9637 has 0.48
- d 2.907 has 2.42
- d 2.8256 has 7.46
- d 2.7914 has 3.61
- d 2.7317 has 1.47
- d 2.6732 has 5.19
- d 2.5863 has 10.62
Claims 20 and 21 are “shortcut” XRPD definitions with reduced peak lists:
- Claim 20: d = 9.45, 7.45, 5.22, 4.40, 4.35, 4.28
- Claim 21: d = 9.45, 7.71, 7.45, 5.22, 4.98, 4.78, 4.40, 4.35, 4.28, 3.38
Practical takeaway: Claim 1 is broadest (peak presence list). Claim 2 narrows by intensity profile. Claims 20/21 create alternate, shorter peak-based definitions that can materially affect infringement testing and claim construction.
How does the “substantially pure” limitation change scope?
- Claim 3: Claim 1 material “in substantially pure form.”
- Claim 4: Claim 2 material “in substantially pure form.”
“Substantially pure” is a qualitative gate that can be argued around during enforcement. But it also provides a design constraint: a competitor’s olanzapine dihydrate material may avoid infringement if it contains enough of another form/impurity so that it is not “substantially pure,” or if it is a different polymorph/dihydrate form rather than D.
What is the explicit B impurity cap?
- Claim 5: Claim 4 material containing less than 2% olanzapine dihydrate B.
This is the most operationally measurable limitation in the independent crystalline-form cluster, because it sets a numeric impurity threshold:
- If a manufacturing process yields dihydrate D with ≥2% dihydrate B, the material may fall outside Claim 5 even if XRPD matches Claim 2/4.
In enforcement, Claim 5 functions as both: (1) additional patent coverage for “clean” D material, and (2) a design-around lever for generics and alternate routes that accept higher B content.
What pharmaceutical formulations are covered by US 6,251,895?
Which dosage forms are explicitly claimed?
- Claim 6: formulation comprising olanzapine dihydrate D of Claim 1 + pharmaceutically acceptable carrier/diluent/excipient.
- Claim 7: formulation comprising olanzapine dihydrate D of Claim 2 + excipient.
- Claim 8: formulation comprising olanzapine dihydrate D of Claim 3 + excipient.
So the patent reaches beyond bulk crystalline material into conventional drug product composition.
Dosage form dependent claims:
- Claim 9: Claim 6 formulation as an aqueous suspension
- Claim 10: Claim 6 formulation as a tablet
- Claim 11: Claim 8 formulation as an aqueous suspension
Infringement risk profile:
- If a competitor uses olanzapine dihydrate D meeting the XRPD definition in a suspension or tablet, the product is within the claimed formulation structure even without asserting a specific excipient package.
- A competitor can still attempt to design around by switching crystalline form (not “D”) or by switching to a dosage form not covered, but the independent formulation claims (6–8) are not limited to a specific dosage form, so a complete carve-out requires avoiding use of the claimed form or avoiding “substantially pure”/impurity conditions.
What medical use claims does US 6,251,895 cover for psychotic and anxiety conditions?
What are the method-of-treatment claims?
- Claim 12: method treating a psychotic condition in a mammal by administering an effective amount of olanzapine dihydrate D of Claim 1.
- Claim 13: method treating a condition selected from:
- anxiety
- schizophrenia
- schizophreniform disorder
- a functional bowel disorder
- psychosis
by administering an effective amount of olanzapine dihydrate D of Claim 1.
Key scope notes:
- The method claims are broad to “a mammal” and use “effective amount” language, which is typically interpreted broadly in practice.
- The “functional bowel disorder” inclusion is notable because it expands beyond psychiatric indications.
Design-around: medical-use design-around is usually not viable for a marketed product because the same active is used for approved indications. The more realistic route is avoiding infringement via the crystalline form definition.
What manufacturing and crystallization process claims are in US 6,251,895?
How does the process claim define formation of dihydrate D?
- Claim 14: process for preparing a crystalline olanzapine dihydrate D:
- stirring technical grade olanzapine in an aqueous solvent
- for about one hour to about six days
- until dihydrate D is formed.
Additional constraints by dependent claims:
- Claim 15: at least 12 hours
- Claim 16: at least 24 hours
- Claim 17: about 5 days
- Claim 18: solvent includes a wetting agent
- Claim 19: includes drying using a technique “sufficiently mild to avoid desolvation of the dihydrate D.”
Claim architecture implication: This is a process-by-steps style claim that can be asserted against manufacturing routes if the process conditions fall within the parameter windows and the product is dihydrate D.
What is the likely practical infringement hook in manufacturing disputes?
A competitor can attempt to avoid the process claims by:
- using a non-aqueous solvent system,
- using different time-temperature profiles that do not fall within the claimed windows,
- adding/removing steps that change whether “dihydrate D” forms,
- using drying conditions that cause partial desolvation (or conversion to a different hydrate/solid form).
But if the end product is dihydrate D and the process matches the claimed ranges, the patent provides a litigation pathway grounded in process evidence.
How do the alternative XRPD definitions in Claims 20 and 21 affect scope and testing?
What do Claims 20 and 21 add?
- Claim 20 uses a reduced peak set: d = 9.45, 7.45, 5.22, 4.40, 4.35, 4.28.
- Claim 21 expands the reduced set: d = 9.45, 7.71, 7.45, 5.22, 4.98, 4.78, 4.40, 4.35, 4.28, 3.38.
Even though Claims 20/21 are narrower in the number of listed peaks, they can still capture a material if those peaks are present at the specified spacings. In XRPD-based infringement, the number and selection of peaks often matters for whether a rival material “matches” the claimed pattern.
Litigation use: these claims can provide additional fallbacks if an accused material matches only a subset (or if intensity comparisons fail under measurement conditions). A defendant may argue that “matching” the reduced set is insufficient to establish that the sample is the same crystalline phase unless the full pattern is shown; a patentee will argue these reduced lists still define the claimed dihydrate D.
How strong is the patent estate for olanzapine dihydrate D versus generic substitution risk?
Strength drivers inside this patent
- Clear crystalline definition: XRPD d-spacing list(s) are the foundation for material identification.
- Numeric impurity limit: “less than 2% dihydrate B” provides a concrete constraint for a common polymorph management question.
- Product and method reach: formulation claims and method claims broaden exposure beyond bulk material.
- Process claim coverage: adds enforcement leverage against manufacturing routes.
Main uncertainty variables (built into scope)
- “Substantially pure” can become a factual dispute: purity thresholds can be argued using different analytical methods and conversion/impurity interpretations.
- XRPD measurement conditions (instrument, sample prep, preferred orientation, humidity during equilibration, scan settings) can alter observed peak positions/intensities.
- The patent’s reduced peak definitions (Claims 20/21) can be litigated around whether they are fully descriptive of the solid form.
What patent lifecycle questions matter for US 6,251,895 exclusivity, generic entry, and Paragraph IV?
No answer is provided here. The user request requires analysis of timelines and Orange Book status, and this cannot be completed accurately from the claim text alone.
More… ↓
⤷ Start Trial
|
